000			02202cam a2200301 4500500
005			20260329022616.0
041			_afre
042			_adc
100	1	0	_aBenzi, Andy _eauthor
700	1	0	_aWuestenberghs, Fabien _eauthor
700	1	0	_aVitton, Véronique _eauthor
700	1	0	_aChambaz, Marion _eauthor
700	1	0	_aRoman, Sabine _eauthor
700	1	0	_aBenech, Nicolas _eauthor
700	1	0	_aDainese, Raffaella _eauthor
700	1	0	_aTakoudju, Céline _eauthor
700	1	0	_aJouët, Pauline _eauthor
700	1	0	_aRaynaud, Jean-Jacques _eauthor
700	1	0	_aGourcerol, Guillaume _eauthor
700	1	0	_aMelchior, Chloé _eauthor
700	1	0	_aMion, François _eauthor
245	0	0	_aRecommendations from the French Neurogastroenterology Group for the diagnosis and management of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO)
260			_c2025.
500			_a96
520			_aThe French Neurogastroenterology Group (GFNG) initiated the drafting of recommendations for the diagnosis and management of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) in adults. A working group developed a total of 25 proposals based on the most recent data from the international scientific literature, addressing the following topics: definition, symptoms, risk factors, diagnostic modalities, and therapeutic approaches. Each statement was assessed using the GRADE methodology to determine its level of evidence (“high,” “moderate,” “low,” or “expert opinion”) and, where applicable, a level of recommendation (“strong,” “moderate,” “weak,” or “very weak”). The proposals were submitted to 22 experts for a two-round vote, in accordance with the Delphi method, resulting in consensus—with over 80% agreement— for 19 proposals on SIBO and 3 on IMO. One proposal on SIBO and 2 on IMO failed to reach consensus, reflecting the complexity of these conditions.
786	0		_nHépato-Gastro & Oncologie Digestive | 32 | 6 | 2025-07-04 | p. 528-552 | 2115-3310
856	4	1	_uhttps://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2025-6-page-528?lang=en&redirect-ssocas=7080
999			_c1921312 _d1921312